Combining anti-VEGF approaches with oxaliplatin in advanced colorectal cancer.

Angiogenesis, the formation of blood vessels, is a vital process in tumor growth and metastasis. Vascular endothelial growth factor (VEGF) is a potential target for antiangiogenic therapy because its overexpression has been associated with tumor vascularity, poor prognosis, and aggressive disease in many malignancies, including colorectal cancer (CRC). Bevacizumab is a recombinant humanized monoclonal antibody against VEGF. It is the first angiogenesis inhibitor to show significant activity in patients and, when combined with chemotherapy, leads to a significant survival benefit in CRC. This monoclonal antibody has been approved for first-line therapy in combination with intravenous 5-fluorouracil-containing regimens in patients with metastatic CRC. Vatalanib (PTK787/ZK222584) is an oral antiangiogenic tyrosine kinase inhibitor of the VEGF receptor. Currently, it is being evaluated in combination with FOLFOX (5-fluorouracil/leucovorin/oxaliplatin) in metastatic CRC. This article reviews the process of angiogenesis and the successful translation of antiangiogenic agents into the clinic. Specifically, studies evaluating VEGF-targeted agents in combination with oxaliplatin-containing regimens in CRC are discussed.